KURA ONCOLOGY, INC. Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31)
KURA ONCOLOGY, INC. (KURA) had Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) of $204.69 thousand as of 2014-12-31, per its 10-K filed 2015-02-27.
Discontinued › Notes
us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage · last filed 2015-02-27
- 2014-12-31: Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) $204.69K.
- 2014-09-30: Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) $193.04K.
- 2014-06-30: Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) $186.61K.
- 2014-03-31: Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) $179.72K.
| Period end | Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) |
|---|---|
| 2014-12-31 | $204.69K 10-K · filed 2015-02-27 |
| 2014-09-30 | $193.04K 10-Q · filed 2014-11-14 |
| 2014-06-30 | $186.61K 10-Q · filed 2014-08-14 |
| 2014-03-31 | $179.72K 10-Q · filed 2014-05-15 |
| 2013-12-31 | $173.96K 10-K · filed 2015-02-27 |
| 2013-09-30 | $164.21K 10-Q · filed 2013-11-14 |
| 2013-06-30 | $158.07K 10-Q · filed 2013-08-14 |
| 2013-03-31 | $151.32K 10-Q · filed 2013-05-15 |
| 2012-12-31 | $145.35K 10-K · filed 2014-03-31 |
| 2012-09-30 | $135.68K 10-Q · filed 2012-11-14 |
| 2012-06-30 | $129.67K 10-Q · filed 2012-08-14 |
| 2012-03-31 | $123.40K 10-Q · filed 2012-05-15 |
| 2011-12-31 | $118.03K 10-K · filed 2013-03-28 |
| 2011-09-30 | $109.15K 10-Q · filed 2011-11-14 |
| 2011-06-30 | $102.88K 10-Q · filed 2011-08-15 |
| 2011-03-31 | $118.03K 10-Q · filed 2012-05-15 |
| 2010-12-31 | $90.99K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |